MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...